Infants experience high rates of invasive meningococcal disease;
however, the currently licensed meningococcal vaccine is poorly immunogenic in infants. In a randomized open-label study, Snape and colleagues Article
assessed the safety and immunogenicity of a novel tetravalent (serogroup A, C, W-135, and Y) meningococcal vaccine (MenACWY) in infants. The primary study outcome was the percentage of infants who had a human complement serum bactericidal activity titer greater than 1:4 against the vaccine meningococcal serogroups,
which was assessed 1 month after receipt of the primary immunization series (at either 2, 3, and 4 months or 2, 4, and 6 months). The authors report that the novel MenACWY vaccine was well tolerated and immunogenic when given according to either vaccination schedule. In an editorial,
Harrison Article discusses vaccine efficacy and progress toward global prevention of meningococcal disease.